AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 292 min read$FTRE

What Fortrea (FTRE) Said on Its Q3 Earnings Call

Fortrea (FTRE) reported Q3 net income of $0.6M, up from a loss of $15.9M YoY. Adjusted net income was $27.9M, and adjusted EPS was $0.28. Operating cash flow improved to $60.8M. The company acquired Early Phase Services, expanding its clinical pharmacology network. Fortrea raised its 2026 revenue guidance to $2.665B-$2.690B and adjusted EBITDA to $210M-$218M. Management expects biotech and biopharma demand recovery.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 5:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Fortrea (FTRE) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$FTREBullishHigh
01

Why it matters

Earnings beat and guidance raise are likely to drive short‑term price appreciation, while integration risk and leverage warrant caution.

02

Market read

The earnings release provides fresh, material data that can influence trading decisions on FTRE and peers in the CRO space.

03

What to watch

Debt level remains high at $845.7M net, and leverage of 3.9x could constrain future financing.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Fortrea Holdings (NASDAQ:FTRE) reported Q3 2026 results, highlighted a turnaround to profitability, completed an acquisition of Early Phase Services, and raised its full‑year revenue and EBITDA outlook.

Company-level read

Ticker impact

$FTREBullishHigh confidence
Context

Q3 earnings released with net income of $0.6M, adjusted EPS $0.28 and raised FY2026 revenue guidance to $2.665‑$2.690B.

Expected impact

likely upward pressure as market prices in improved earnings and higher guidance

Evidence & confidence

The company posted a profit after a loss year‑over‑year and lifted its revenue outlook, which typically supports a price rally.

Market effects

Sector

CRO sector may see broader optimism as a peer demonstrates profitability and guidance upgrades.

Regional

U.S. biotech and CRO stocks could experience modest gains.

Global

Limited to investors focused on clinical research services.

Counterpoint

What could challenge this read

Higher guidance may already be priced in; execution risk on integration could limit upside.

Key entities

  • company
    Fortrea Holdings Inc.

    Global contract research organization providing CRO services.

  • company
    Worldwide Clinical Trials

    Seller of the Early Phase Services business acquired by Fortrea.

Read at source← All news

StoryFortrea reports Q3 2026 results, raises full‑year guidance but EPS misses consensus

Also covered by

4 outlets

Related articles

OCT 30
$FTREMed

Truist raises Fortrea stock price target to $29 on margin outlook

Truist Securities raised its price target on Fortrea (NASDAQ:FTRE) to $29 from $26, maintaining a Buy rating. The stock trades at $23.14 with a $2.23B market cap. Fortrea reported a TTM book-to-bill ratio of 1.12x, below expectations, and expects Q4 adjusted EBITDA of $50M with a 7.5% margin, down from Q3. The company cited fewer working days and investments for the decline, but noted six consecutive quarters of margin upside and improving biotech demand.

investing.com2 min
OCT 30
$FTREMed

Fortrea Holdings Inc (FTRE) (Q3 2026) Earnings Call Highlights: Backlog Cleanup

Fortrea Holdings (FTRE) reported a $558M backlog adjustment, not impacting near-term revenue. Q4 EBITDA guidance was lowered due to fewer working days and IT investment. Gross margins improved from portfolio mix and efficiencies. CEO Anshul Thakral and CFO Jason Knobloch discussed growth strategies, including acquisitions like Worldwide Clinical Trials, and market recovery trends in biotech and biopharma. The company aims for mid-teens EBITDA margins and sees increasing RFP activity.

finance.yahoo.com2 min
OCT 29
$FTREHighAI 8/10

Fortrea (FTRE) Q3 2026 Earnings Call Transcript

Fortrea (FTRE) reported Q3 2026 revenue of $691.5M, adjusted EBITDA of $58M, and a book-to-bill ratio of 1.12x. The company raised full-year guidance and completed an acquisition to expand its clinical pharmacology capacity. Fortrea's strategy focuses on revenue growth and margin expansion through commercial, operational, and financial excellence.

finance.yahoo.com3 min
OCT 29
$FTREHighAI 8/10

Fortrea Q3 2026 slides: EBITDA rises 14% as revenue falls short

Fortrea Holdings (FTRE) reported Q3 2026 revenue of $691.5M, down 1.4% YoY, missing estimates by $200.83M. Adjusted EBITDA rose 14.4% to $58.0M, with margins expanding to 8.4%. EPS missed by 55.6%, and the stock fell 11% premarket. Management raised full-year guidance but warned of Q4 revenue decline. The company acquired Worldwide Clinical Trials’ Early Phase Services for $45M, improving cash flow and liquidity.

investing.com3 min